Research Progress in the Treatment of Hormone Receptor/Human Epidermal Growth Factor Receptor 2-positive Breast Cancer
1.Department of Head and Neck Oncology,West China Hospital,Sichuan University,Chengdu 610041,China
2.Clinical Research Center for Breast,West China Hospital,Sichuan University,Chengdu 610041,China
*Corresponding author:LUO Ting,Associate professor;E-mail:tina621@163.com
WU Yanqi,LUO Ting. Research Progress in the Treatment of Hormone Receptor/Human Epidermal Growth Factor Receptor 2-positive Breast Cancer [J]. Chinese General Practice, 2021, 24(8): 1028-1032. DOI: 10.12114/j.issn.1007-9572.2019.00.744.
伍雁琦,罗婷. 激素受体/人表皮生长因子受体2阳性乳腺癌治疗研究进展[J]. 中国全科医学, 2021, 24(8): 1028-1032. DOI: 10.12114/j.issn.1007-9572.2019.00.744.
[1]郑荣寿,孙可欣,张思维,等.2015年中国恶性肿瘤流行情况分析[J].中华肿瘤杂志,2019,41(1):19-28.DOI:10.3760/cma.j.issn.0253-3766.2019.01.005.
ZHENG R S,SUN K X,ZHANG S W,et al.Report of cancer epidemiology in China,2015[J].Chinese Journal of Oncology,2019,41(1):19-28.DOI:10.3760/cma.j.issn.0253-3766.2019.01.005.
[2]OWENS M A,HORTEN B C,DA SILVA M M.HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues[J].Clin Breast Cancer,2004,5(1):63-69.
[3]PRAT A,BASELGA J.The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2[J].Nat Clin Pract Oncol,2008,5(9):531-542.DOI:10.1038/ncponc1179.
[4]LAL P,TAN L K,CHEN B Y.Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomas[J].Am J Clin Pathol,2005,123(4):541-546.DOI:10.1309/YMJ3-A83T-B39M-RUT9.
[5]HOWLADER N,ALTEKRUSE S F,LI C I,et al.US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status[J].J Natl Cancer Inst,2014,106(5):dju055.DOI:10.1093/jnci/dju055.
[6]VICI P,PIZZUTI L,NATOLI C,et al.Triple positive breast cancer:a distinct subtype?[J].Cancer Treat Rev,2015,41(2):69-76.DOI:10.1016/j.ctrv.2014.12.005.
[7]OSBORNE C K,SCHIFF R.Mechanisms of endocrine resistance in breast cancer[J].Annu Rev Med,2011,62:233-247.DOI:10.1146/annurev-med-070909-182917.
[8]DE LAURENTIIS M,ARPINO G,MASSARELLI E,et al.A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer[J].Clin Cancer Res,2005,11(13):4741-4748.DOI:10.1158/1078-0432.CCR-04-2569.
[9]ARPINO G,WIECHMANN L,OSBORNE C K,et al.Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family:molecular mechanism and clinical implications for endocrine therapy resistance[J].Endocr Rev,2008,29(2):217-233.DOI:10.1210/er.2006-0045.
[10]LOI S,DAFNI U,KARLIS D,et al.Effects of estrogen receptor and human epidermal growth factor receptor-2 levels on the efficacy of trastuzumab:a secondary analysis of the HERA trial[J].JAMA Oncology,2016,2(8):1040-1047.DOI:10.1001/jamaoncol.2016.0339.
[11]VICI P,PIZZUTI L,SPERDUTI I,et al.“Triple positive” early breast cancer:an observational multicenter retrospective analysis of outcome[J].Oncotarget,2016,7(14):17932-17944.DOI:10.18632/oncotarget.7480.
[12]ALQAISI A,CHEN L,ROMOND E,et al.Impact of estrogen receptor(ER) and human epidermal growth factor receptor-2(HER2) co-expression on breast cancer disease characteristics:implications for tumor biology and research[J].Breast Cancer Res Treat,2014,148(2):437-444.DOI:10.1007/s10549-014-3145-x.
[13]YOU S H,CHAE B J,EOM Y H,et al.Clinical differences in triple-positive operable breast cancer subtypes in Korean patients:an analysis of Korean breast cancer registry data[J].J Breast Cancer,2018,21(4):415-424.DOI:10.4048/jbc.2018.21.e53.
[14]刘海盟,王晓珍,李嗣杰,等.三阳性乳腺癌与Her-2过表达型乳腺癌预后对比的临床研究[J].中国实验诊断学,2018,22(4):615-617.DOI:10.3969/j.issn.1007-4287.2018.04.014.http://cdmd.cnki.com.cn/Article/CDMD-10183-1018218991.htm.
[15]MONTEMURRO F,DI COSIMO S,ARPINO G.Human epidermal growth factor receptor 2(HER2)-positive and hormone receptor-positive breast cancer:new insights into molecular interactions and clinical implications[J].Ann Oncol,2013,24(11):2715-2724.DOI:10.1093/annonc/mdt287.
[16]CORTES J,BASELGA J.How to treat hormone receptor-positive,human epidermal growth factor receptor 2-amplified breast cancer[J].J Clin Oncol,2009,27(33):5492-5494.DOI:10.1200/JCO.2009.23.8089.
[17]SLAMON D J,LEYLAND-JONES B,SHAK S,et al.Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2[J].N Engl J Med,2001,344(11):783-792.DOI:10.1056/NEJM200103153441101.
[18]VERMA S,MILES D,GIANNI L,et al.Trastuzumab emtansine for HER2-positive advanced breast cancer[J].N Engl J Med,2012,367(19):1783-1791.DOI:10.1056/nejmoa1209124.
[19]BASELGA J,CORTéS J,KIM S B,et al.Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer[J].N Engl J Med,2012,366(2):109-119.DOI:10.1056/NEJMoa1113216.
[20]CAMERON D,PICCART-GEBHART M J,GELBER R D,et al.
11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer:final analysis of the HERceptin Adjuvant(HERA) trial[J].Lancet,2017,389(10075):1195-1205.DOI:10.1016/S0140-6736(16)32616-2.
[21]GIANNI L,EIERMANN W,SEMIGLAZOV V,et al.Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer(NOAH):follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort[J].Lancet Oncol,2014,15(6):640-647.DOI:10.1016/S1470-2045(14)70080-4.
[22]VON MINCKWITZ G,PROCTER M,DE AZAMBUJA E,et al.Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer[J].N Engl J Med,2017,377(2):122-131.DOI:10.1056/nejmoa1703643.
[23]GIANNI L,PIENKOWSKI T,IM Y H,et al.5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced,inflammatory,or early-stage HER2-positive breast cancer(NeoSphere):a multicentre,open-label,phase 2 randomised trial[J].Lancet Oncol,2016,17(6):791-800.DOI:10.1016/S1470-2045(16)00163-7.
[24]SWAIN S M,BASELGA J,KIM S B,et al.Pertuzumab,trastuzumab,and docetaxel in HER2-positive metastatic breast cancer[J].N Engl J Med,2015,372(8):724-734.DOI:10.1056/NEJMoa1413513.
[25]PEREZ E A,BARRIOS C,EIERMANN W,et al.Trastuzumab emtansine with or without pertuzumab versus trastuzumab plus taxane for human epidermal growth factor receptor 2-positive,advanced breast cancer:primary results from the phaseⅢ MARIANNE study[J].J Clin Oncol,2017,35(2):141-148.DOI:10.1200/JCO.2016.67.4887.
[26]DIéRAS V,MILES D,VERMA S,et al.Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer(EMILIA):a descriptive analysis of final overall survival results from a randomised,open-label,phase 3 trial[J].Lancet Oncol,2017,18(6):732-742.DOI:10.1016/S1470-2045(17)30312-1.
[27]KROP I E,KIM S B,GONZáLEZ-MARTíN A,et al.Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer(TH3RESA):a randomised,open-label,phase 3 trial[J].Lancet Oncol,2014,15(7):689-699.DOI:10.1016/S1470-2045(14)70178-0.
[28]HURVITZ S A,MARTIN M,SYMMANS W F,et al.Neoadjuvant trastuzumab,pertuzumab,and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer(KRISTINE):a randomised,open-label,multicentre,phase 3 trial[J].Lancet Oncol,2018,19(1):115-126.DOI:10.1016/S1470-2045(17)30716-7.
[29]SCHNEEWEISS A,CHIA S,HICKISH T,et al.Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer:a randomized phase Ⅱcardiac safety study(TRYPHAENA)[J].Ann Oncol,2013,24(9):2278-2284.DOI:10.1093/annonc/mdt182.
[30]中国临床肿瘤学会指南工作委员会.中国临床肿瘤学会(CSCO)乳腺癌诊疗指南(2019)[M].北京:人民卫生出版社,2019.
[31]National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines in Oncology.Breast cancer,version 2.2019[M].https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf.
[32]CARDOSO F,SENKUS E,COSTA A,et al.4th ESO-ESMO international consensus guidelines for advanced breast cancer(ABC 4)[J].Ann Oncol,2018,29(8):1634-1657.DOI:10.1093/annonc/mdy192.
[33]KAUFMAN B,MACKEY J R,CLEMENS M R,et al.Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive,hormone receptor-positive metastatic breast cancer:results from the randomized phaseⅢ TAnDEM study[J].J Clin Oncol,2009,27(33):5529-5537.DOI:10.1200/JCO.2008.20.6847.
[34]SWAIN S M,KIM S B,CORTéS J,et al.Pertuzumab,trastuzumab,and docetaxel for HER2-positive metastatic breast cancer(CLEOPATRA study):overall survival results from a randomised,double-blind,placebo-controlled,phase 3 study[J].Lancet Oncol,2013,14(6):461-471.DOI:10.1016/S1470-2045(13)70130-X.
[35]RIMAWI M,FERRERO J M,DE LA HABA-RODRIGUEZ J,et al.First-line trastuzumab plus an aromatase inhibitor,with or without pertuzumab,in human epidermal growth factor receptor 2-positive and hormone receptor-positive metastatic or locally advanced breast cancer(PERTAIN):a randomized,open-label phase Ⅱ trial[J].J Clin Oncol,2018,36(28):2826-2835.DOI:10.1200/JCO.2017.76.7863.
[36]JOHNSTON S R D,HEGG R,IM S A,et al.PhaseⅢ,randomized study of dual human epidermal growth factor receptor 2(HER2) blockade with lapatinib plus trastuzumab in combination with an aromatase inhibitor in postmenopausal women with HER2-positive,hormone receptor-positive metastatic breast cancer:ALTERNATIVE[J].J Clin Oncol,2018,36(8):741-748.DOI:10.1200/JCO.2017.74.7824.
[37]FINN R S,DERING J,CONKLIN D,et al.PD 0332991,a selective cyclin D kinase 4/6 inhibitor,preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro[J].Breast Cancer Res,2009,11(5):R77.DOI:10.1186/bcr2419.
[38]SLEDGE G W Jr,TOI M,NEVEN P,et al.MONARCH 2:abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy[J].J Clin Oncol,2017,35(25):2875-2884.DOI:10.1200/JCO.2017.73.7585.
[39]GOEL S,WANG Q,WATT A C,et al.Overcoming therapeutic resistance in HER2-positive breast cancers with CDK4/6 inhibitors[J].Cancer Cell,2016,29(3):255-269.DOI:10.1016/j.ccell.2016.02.006.
[40]WITKIEWICZ A K,COX D,KNUDSEN E S.CDK4/6 inhibition provides a potent adjunct to HER2-targeted therapies in preclinical breast cancer models[J].Genes Cancer,2014,5(7/8):261-272.DOI:10.18632/genesandcancer.24.
[41]GIANNI L,BISAGNI G,COLLEONI M,et al.Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive,ER-positive breast cancer(NA-PHER2):an exploratory,open-label,phase 2 study[J].Lancet Oncol,2018,19(2):249-256.DOI:10.1016/S1470-2045(18)30001-9.
[42]SOLTI Breast Cancer Research Group.Study of palbociclib and trastuzumab with endocrine therapy in HER2-positive metastatic breast cancer[EB/OL].[2019-10-11].https://clinicaltrials.gov/ct2/show/NCT02448420?cond=PATRICIA&rank=1.
[43]Alliance Foundation Trials,LLC.Randomized,Open Label,Clinical Study of the Targeted Therapy,Palbociclib,to treat metastatic breast cancer(PATINA)[EB/OL].[2019-10-11].https://clinicaltrials.gov/ct2/show/NCT02947685?term=PATINA&rank=1.
[44]Eli Lilly and Company.A study of abemaciclib(LY2835219) in women with HR+,HER2+ locally advanced or metastatic breast cancer(monarcHER)[EB/OL].[2019-10-11].https://clinicaltrials.gov/ct2/show/NCT02675231?term=monarcHER&rank=1.
[45]International Breast Cancer Study Group.To reduce the use of chemotherapy in elderly patients with ER-positive and HER2-positive breast cancer(TOUCH)[EB/OL].[2019-10-11].https://clinicaltrials.gov/ct2/show/NCT03644186?term=TOUCH&cond=Breast+Cancer&rank=1.
[46]International Breast Cancer Study Group.Anti-PD-1 monoclonal antibody in advanced,trastuzumab-resistant,HER2-positive breast cancer(PANACEA)[EB/OL].[2019-10-11].https://clinicaltrials.gov/ct2/show/NCT02129556?term=PANACEA&rank=3.
[47]Fondazione Michelangelo.Neoadjuvant treatment of HER2 positive early high-risk and locally advanced breast cancer(APTneo)[EB/OL].[2019-10-11].https://clinicaltrials.gov/ct2/show/NCT03595592?term=APTneo&rank=1.
[48]National Cancer Institute(NCI).Paclitaxel,trastuzumab,and pertuzumab with or without atezolizumab in treating patients with metastatic breast cancer[EB/OL].[2019-10-11].https://clinicaltrials.gov/ct2/show/NCT03199885?cond=Breast+Cancer&intr=Atezolizumab+Trastuzumab&rank=5.
[49]YARDLEY D A,NOGUCHI S,PRITCHARD K I,et al.Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer:BOLERO-2 final progression-free survival analysis[J].Adv Ther,2013,30(10):870-884.DOI:10.1007/s12325-013-0060-1.
[50]HURVITZ S A,ANDRE F,JIANG Z F,et al.Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer(BOLERO-1):a phase 3,randomised,double-blind,multicentre trial[J].Lancet Oncol,2015,16(7):816-829.DOI:10.1016/S1470-2045(15)00051-0.
[51]ANDRé F,O'REGAN R,OZGUROGLU M,et al.Everolimus for women with trastuzumab-resistant,HER2-positive,advanced breast cancer(BOLERO-3):a randomised,double-blind,placebo-controlled phase 3 trial[J].Lancet Oncol,2014,15(6):580-591.DOI:10.1016/S1470-2045(14)70138-X.
[52]ANDRé F,HURVITZ S,FASOLO A,et al.Molecular alterations and everolimus efficacy in human epidermal growth factor receptor 2-overexpressing metastatic breast cancers:combined exploratory biomarker analysis from BOLERO-1 and BOLERO-3[J].J Clin Oncol,2016,34(18):2115-2124.DOI:10.1200/JCO.2015.63.9161.
[53]LOIBL S,DE LA PENA L,NEKLJUDOVA V,et al.Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer:a randomised,double-blind,placebo-controlled phase Ⅱ trial(NeoPHOEBE)[J].Eur J Cancer,2017,85:133-145.DOI:10.1016/j.ejca.2017.08.020.
[54]SIROHI B,RASTOGI S,DAWOOD S.Buparlisib in breast cancer[J].Future Oncol,2015,11(10):1463-1470.DOI:10.2217/fon.15.56.
[55]JAIN S,SHAH A N,SANTA-MARIA C A,et al.Phase Ⅰ study of alpelisib(BYL-719) and trastuzumab emtansine(T-DM1) in HER2-positive metastatic breast cancer(MBC) after trastuzumab and taxane therapy[J].Breast Cancer Res Treat,2018,171(2):371-381.DOI:10.1007/s10549-018-4792-0.
[56]CHARI R V,MILLER M L,WIDDISON W C.Antibody-drug conjugates:an emerging concept in cancer therapy[J].Angew Chem Int Ed Engl,2014,53(15):3796-3827.DOI:10.1002/anie.201307628.
[57]LEWIS PHILLIPS G D,LI G M,DUGGER D L,et al.Targeting HER2-positive breast cancer with trastuzumab-DM1,an antibody-cytotoxic drug conjugate[J].Cancer Res,2008,68(22):9280-9290.DOI:10.1158/0008-5472.CAN-08-1776.
[58]PEDDI P F,HURVITZ S A.Trastuzumab emtansine:the first targeted chemotherapy for treatment of breast cancer[J].Future Oncol,2013,9(3):319-326.DOI:10.2217/fon.13.7.
[59]VON MINCKWITZ G,HUANG C S,MANO M S,et al.Trastuzumab emtansine for residual invasive HER2-positive breast cancer[J].N Engl J Med,2019,380(7):617-628.DOI:10.1056/NEJMoa1814017.
[60]HARBECK N,GLUZ O,CHRISTGEN M,et al.De-escalation strategies in human epidermal growth factor receptor 2(HER2)-positive early breast cancer(BC):final analysis of the West German study group adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early BC HER2- and hormone receptor-positive phase Ⅱ randomized trial-efficacy,safety,and predictive markers for 12 weeks of neoadjuvant trastuzumab emtansine with or without endocrine therapy(ET) versus trastuzumab plus ET[J].J Clin Oncol,2017,35(26):3046-3054.DOI:10.1200/JCO.2016.71.9815.